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Objective
To evaluate the feasibility of day and night closed-loop insulin delivery in adults with type 1 diabetes under free-living conditions.
Methods
Seventeen adults with type 1 diabetes on insulin pump therapy [age 34±9years; HbA1c 7.6±0.8%; duration of diabetes 19±9years; mean±SD] participated in an openlabel multinational three-centre cross-over study. In a random order participants underwent two eight day periods (first day at the clinical research facility followed by seven days at home) of sensor augmented insulin pump therapy or automated closed-loop insulin delivery. The primary endpoint was the time when sensor glucose was in target range between 3.9 and 10.0 mmol/l during the seven day home phase.
Results
During the home phase, the percentage time when glucose was in target range was significantly higher during closed-loop compared to sensor augmented pump therapy mmol/l, p=0.027) and time spent above target (p=0.013) were lower during closedloop while time spent below target was comparable (p=0.339). Increased time in target was observed during both day-time (p=0.017) and night-time (p=0.013).
Despite significant improvements in the care of type 1 diabetes, achieving good glycaemic control while avoiding hypoglycaemia (1) remains a challenge for many patients (2; 3). Insulin pump therapy and real time continuous glucose monitoring (CGM) have shown to improve HbA1c (4; 5) and reduce hypoglycaemia (6; 7) particularly when using low glucose suspend (8; 9) . Closed-loop insulin delivery is an emerging treatment option combining these technological advances (10) to modulate delivery of insulin in a glucose responsive fashion. Closed-loop differs from conventional pump therapy, characterised by pre-programmed basal delivery, through the use of a control algorithm which directs subcutaneous insulin delivery according to sensor glucose levels. Several studies have evaluated the safety and efficacy of closed-loop under laboratory conditions and shown promising results.
These include evaluations using a randomised design by our group in youths (11; 12) , adults (13) , and pregnant women (14) and by others using the model predictive control algorithm (15; 16) , the proportional-integral-derivative approach (17; 18) , and the fuzzy logic controller (19; 20) . Insulin and glucagon co-administration have also been applied in studies (21) (22) (23) .
In contrast to studies conducted in the clinical research facility with carefully controlled conditions, closed-loop at home is exposed to considerably more varied meal and exercise patterns. Participants may over-or underestimate carbohydrate content and may undertake unplanned activity and/or exercise. Patients using insulin pump therapy are advised to use temporary reductions or increments of basal insulin delivery to meet these demands but this requires a degree of planning and user intuition and interaction. Since closed-loop systems modulate delivery of insulin in a glucose responsive fashion (10) , it may be able to achieve better glucose control than pre-programmed basal rates of conventional pump therapy.
In February 2010, the European Union granted funding to the AP@home consortium of European academic medical centres, biotechnology companies and industrial partners to carry out closed-loop glucose control research (24) . The first major closed-loop study performed by the AP@home consortium evaluated the feasibility of day and night closed-loop insulin delivery using two different algorithms in 47 adults with type 1 diabetes (25) . The present study was undertaken to evaluate the performance of day and night closed-loop insulin delivery with Cambridge algorithm over seven days at home preceded by one day control at the clinical research facility.
METHODS
Participants and study design
The study adopted an open-label prospective multinational three-centre randomised cross-over design. The study protocol was approved by respective research ethics committees and regulatory authorities in the UK, Germany and Austria. Study participants were recruited between January 2013 and August 2013 through adult diabetes clinics and other established methods at each participating centre (Addenbrooke's Hospital, Cambridge, UK; Profil Institute, Neuss, Germany;
and Medical University of Graz, Graz, Austria). Key inclusion criteria were age ≥18 years, diagnosis of type 1 diabetes, treatment with insulin pump therapy for at least 3 months, willingness to perform at least six finger-stick glucose measurements per day, and HbA1c ≤10% (86 mmol/mol). Key exclusion criteria were concurrent illness or medications likely to interfere with interpretation of study results, recurrent severe hypoglycaemia, significant hypoglycaemia unawareness, total daily insulin dose ≥ 2.0 U/kg, clinically significant nephropathy, neuropathy, or retinopathy, severe visual or hearing impairment, pregnancy and breast feeding. All participants provided written informed consent prior to study related activities.
Study procedures:
After enrolment, participants were trained on the use of study insulin pump (Dana R Diabecare, Sooil, Seoul, South Korea) and continuous glucose monitoring device (FreeStyle Navigator, Abbott Diabetes Care, Alameda, CA, USA) (26) . The study insulin pump was programmed with participant's usual basal settings as well as usual insulin to carbohydrate ratios and correction factors. Participants were advised to use the bolus calculator for all meals during the entire study period. Ability to use study devices was formally assessed using competency assessment and additional training was provided as required. After a run-in period of seven days to three weeks, participants underwent two eight day periods; in random order, when glucose was controlled either by sensor augmented insulin pump therapy (SAP) or closed-loop insulin delivery. The first day of each study period was conducted at a clinical research facility. After the first day, participants continued study interventions for the next seven days under free-living conditions in their home and work environment.
The two intervention periods were separated by a one to four week washout. No changes were made to usual treatment parameters. Participants were advised to calibrate the CGM device according to manufacturer's instructions (26) and use the built-in glucometer for all finger-stick measurements and to keep a diary for detailed documentation.
Inpatient stay
At the start of each study intervention, participants were admitted to the clinical research facility around 07:30 hours. On arrival, an intravenous cannula was inserted to allow for frequent venous sampling starting at 08:30 hours. Venous blood samples were collected at 30 minute intervals for the measurement of plasma glucose between 08:30 and 23:00 hours followed by every 60 minutes thereafter till 07:00 hours the following morning. Closed-loop and SAP treatment commenced at 09:00 hours with breakfast.
Participants consumed standardized meals; breakfast 50 g, lunch 60 g and dinner 80 g of carbohydrates; at 09:00, 13:00 and 20:00 hours. Fifteen minutes before each meal an insulin bolus was delivered, calculated according to usual settings and pre-meal finger-stick glucose levels. The insulin bolus was given with the meal if finger-stick glucose was ≤4.0 mmol/l. Meal content and bolus procedure of each study intervention was identical. Participants consumed optional snacks containing 20g carbohydrate at 16:00 hours and 15g carbohydrate at 22:00 hours.
During the closed-loop visit, no insulin bolus was given for snacks but during the SAP visit participants received pre-snack bolus as per usual practice. Rapid-acting insulin analogue aspart (Novo Nordisk, Bagsvaerd, Denmark) was used throughout the study. During the closed-loop visit, participants received additional training on starting, stopping, and safe operation of the closed-loop system. Competency on the use of closed-loop system was assessed by the study team prior to discharge.
Home phase
Seven day home phase commenced at the end of the one day inpatient stay.
Participants were provided with a custom made pouch to carry the small portable computer running the algorithm and CGM device (Supplemental Online Material, Figure S1 ). As a precaution, participants were advised not to drive or undertake strenuous physical exercise while the closed-loop system was in operation but were encouraged to engage in usual daily activities including going to work and moderate activity such as walking and daily housework. Participants were provided with a 24-hour telephone helpline and were advised to follow usual treatment guidelines during inter-current illness, hyperglycaemia and hypoglycaemia. They were free to consume meals of choice including eating out. During closed-loop intervention, participants
were not required to give insulin bolus for snacks below 30 g of carbohydrate and during both study interventions participants were free to decide on alarm thresholds for the CGM device.
Closed-loop system
The Florence closed-loop system (University of Cambridge, Cambridge, UK) (27) comprises a model predictive control algorithm residing on an ultraportable laptop (OQO Model 02 computer, OQO, CA, USA), which is linked to the CGM receiver by a USB cable and controls the study pump over wireless communication.
Every 12 minutes, the algorithm calculated a new insulin infusion rate which was automatically sent to the study insulin pump. The calculations utilised a compartment model of glucose kinetics (28) describing the effect of rapid-acting insulin analogues and the carbohydrate content of meals on glucose levels. Participants were required to count the carbohydrates and use the pump bolus calculator for pre-meal boluses as per usual practice. Meal bolus also included a correction bolus as calculated by the bolus wizard if the glucose was outside target range.
Carbohydrate content of consumed meals and insulin delivery history including manually instructed bolus, were downloaded automatically from the study pump. The algorithm was initialized using pre-programmed basal insulin delivery downloaded from the study pump. Additionally, participant's weight and total daily insulin dose were entered at setup. During closed-loop operation, the algorithm adapted itself to a particular participant. The treat-to-target control algorithm aimed to achieve glucose levels between 5.8 and 7. 
Safety precautions during closed-loop
Participants were trained to perform calibration check before breakfast and evening meal. If sensor glucose was above finger-stick glucose by more than 3 mmol/l, the CGM was re-calibrated. There was no re-calibration for sensor under reading. These instructions resulted from an in silico evaluation of hypoglycaemia and hyperglycaemia risk (29) using the validated Cambridge simulator (30) .
If sensor glucose became unavailable, pre-programmed insulin delivery was automatically restarted within 30 minutes or within 1 hour in case of other failures.
This limited the risk of insulin under-and over-delivery (29) . Safety rules limited maximum insulin infusion and suspended insulin delivery at sensor glucose at or <4.3mmol/l or when sensor glucose was rapidly decreasing.
Assays
During the in-patient stay, a YSI2300 STAT Plus Analyzer (YSI, Lynchford House, Farnborough, UK; intra-assay coefficient of variation (CV) 1.5% and interassay CV 2.8%) was used for determination of plasma glucose.
Statistical analysis
The analysis plan was agreed in advance. All analyses were undertaken on intention to treat basis. The primary outcome was the time when glucose was in the target range 3.9 to 10.0 mmol/l during the home study phase. Secondary outcomes were mean glucose, time when glucose was <3.9 mmol/l and <2.8 mmol/l (hypoglycaemia), time when glucose was >10.0 mmol/l and >16.7 mmol/l (hyperglycaemia), low and high blood glucose index and insulin delivery. We estimated glycaemic variability by the standard deviation of glucose and the coefficient of variation. The low and high blood glucose index assessing the duration and extent of hypo-and hyperglycaemia was calculated as an average of transformed glucose measurements progressively increasing at low and high glucose levels (31). We corrected for bias resulting from simultaneous use of sensor glucose to direct insulin delivery and to assess outcomes by using adjusted glucose -a stochastic transformation of glucose metrics when assessing time glucose was in, below, and above target range (32) . Other glucose metrics such as mean glucose and glucose variability were calculated utilising native (unadjusted) sensor glucose levels.
Secondary outcomes were calculated for the one day inpatient stay, seven day home phase as a whole and daytime (07:00 till 23:00 hours) and overnight (23:00 till 07:00 hours) periods. During the inpatient stay, study outcomes were calculated using both YSI laboratory glucose measurements and sensor glucose. Calculations were made using GStat software, Version 2.0 (University of Cambridge). Statistical analyses were conducted with the use of SPSS, Version 19 (IBM Software, Hampshire, UK).
Normally distributed data were compared using paired t-test while non-normally distributed data were compared using Wilcoxon signed rank test. Values are reported as mean±SD or median (interquartile range: quartile 1 to quartile 3) unless stated otherwise. All p-values are two-tailed and values less than 0.05 were considered statistically significant.
RESULTS
From January 2013 to August 2013, 24 volunteers were screened and 21 enrolled. Four dropouts were recorded, two during the first study period, one during the run-in phase, and another during the washout period leaving 17 completed participants [age 34±9 years; HbA1c 7.6±0.8%; duration of diabetes 19±9 years; duration of pump therapy 5.6±6.9 years; Supplemental Online Material Table S1 ].
Glucose control and insulin delivery during the home phase
The primary study outcome, the adjusted time spent in target glucose range 3.9 to 10.0 mmol/l at home, was higher during closed-loop insulin delivery (74.5 Table S2 ) concurred with the assessment by adjusted values ( Table 1) .
As expected, variability of basal insulin delivery was significantly higher during closed-loop (Table 2 ). Bolus and basal insulin infused during day was significantly different between the two interventions; during closed-loop period lower bolus amount and higher basal dose were observed. Overall there was tendency towards lower total daily dose during closed-loop but this did not reach statistical significance (p=0.109).
Day and night glucose control during the home phase
Closed-loop increased time in target during both day-time (target 3.9 to 10.0 mmol, 72.5% vs. 65.4%, p=0.017) and night-time (target 3.9 to 8.0 mmol/l, 48.4% vs.
35.1%, p=0.013) ( Table 2 ). In addition, mean sensor glucose was lower during nighttime period (8.3 ± 1.3 vs. 9.3 ± 1.1, p=0.015). There was no difference in the area under the curve for hypoglycaemia during either period (Table 2) .
Glucose control and insulin delivery during the one day inpatient stay
Time spent in target glucose range 3.9 to 10.0 mmol/l was higher with closedloop during the inpatient stay (YSI based results Table 1 and CGM based results Table S3 ). The number of rescue carbohydrate treatments required was lower during closed-loop (closed-loop 7 vs. SAP 16) but did not reach statistical significance (p=0.215). Closed-loop administered significantly lower total insulin daily dose during the inpatient stay (36.8 vs. 41.8 U, p=0.028).
Supplemental Online Material
Sensor accuracy during inpatient stay
Sensor performance was good with median absolute deviation of 0. Table S4 . Eighty three percent of YSI-sensor pairs were in Clarke Error Grid Zone A.
Adverse events
Two severe hypoglycaemic events occurred during the study; one event during closed-loop arm and one event during washout period. The severe hypoglycaemia event during the closed-loop period occurred at a time when closedloop was non-operational due to sensor unavailability and insulin was being delivered according to participant's usual pump settings. The second severe hypoglycaemia episode leading to hospital admission occurred during washout while the participant was using usual pump treatment in the context of inter-current illness. Both 
CONCLUSIONS
The present study demonstrates the feasibility of unsupervised day and night closed-loop insulin delivery under free-living conditions in adults with type 1 diabetes.
When applied in a relatively well controlled cohort, compared to current best therapy, closed-loop increased the time when glucose was in the target range while reducing the mean glucose. Importantly, these improvements were achieved without increasing the risk of hypoglycaemia while administering similar amount of total daily insulin dose. Benefits of closed-loop were more pronounced during the overnight period although glucose control was superior during both day and night time. Other benefits include reduced glucose variability as measured by standard deviation and reduced high glucose excursions. In agreement with results obtained during the seven day home phase, participants also showed improved plasma glucose control with closed-loop during the one day stay at the clinical research facility while infusing a significantly lower amount of insulin.
In the current study there was no statistically significant decrease in the time spent in hypoglycaemia. This can be explained by the study not being powered to detect such a difference although trend towards a lower hypoglycaemia exposure was observed (AUC below 3.5 mmol/l 71% lower during closed-loop; 2.9% vs 7.9%, CL vs SAP; p=0.14). Low levels of hypoglycaemia were observed compared to, for example, Juvenile Diabetes Research Foundation CGM trial (5) which recorded time spent in hypoglycaemia (< 3.9 mmol) of 89 and 60 minutes per day prior and after the use of real time CGM. Participants in the present study spent 40 and 49 minutes per day during closed loop and control periods; excluding subjects with significant co-morbidities and hypoglycaemia unawareness may have led to selection of participants with a lower hypoglycaemia risk.
A smart phone based closed-loop control platform was previously evaluated in 20 adults in four clinical centres in a non-randomised single arm study design in a home like environment (hotel / guest house or mixed hospital-hotel admissions) (33).
The study duration was 42 hours with first 14 hours of operation under open loop control followed by 28 hours of closed-loop. In contrast, out-patient closed-loop duration in the present study was longer at 168 hours per participant. Two further randomised crossover studies have evaluated the use of overnight closed-loop outside clinical research facility. The first study showed reduced rates of hypoglycaemia during a single night at three youth diabetes camps (34) . An interim analysis from the second study using closed-loop at home for four nights have also shown reduced hypoglycaemia burden (35) . Feasibility of dual hormone closed-loop under free living conditions at home for 48 hours have been evaluated but despite the use of glucagon this study reported more hypoglycaemia during closed-loop arm (36) .
During the present proof-of-concept study, a prototype closed-loop system was used with the objective to assess the feasibility of day and night hybrid closedloop. Participants were required to carry the ultra-portable computer in a removable pouch. When CGM was available closed-loop was operational over 90% of time during the home phase. Based on encouraging results from the current study, a closed-loop system based on smart phone technology suitable for longer studies is under development. During current study, there was no dedicated treatment optimisation period and participants were only informed about insulin requirements in each study period after completion of the study minimising any influence arising from the cross over study design.
Training on closed-loop system took about 60 minutes. Closed-loop technology appears simple to initiate once insulin pump therapy and continuous glucose monitoring is established. A more comprehensive training was administered at study start, to familiarise participants with the study pump and continuous glucose monitoring. The two severe hypoglycaemic events seen during current study were unrelated to closed-loop insulin delivery.
The strengths of our study are the integration of closed-loop into normal life including use at work, weekends, holidays, varied diet and sleeping patterns and randomised crossover study design in multinational multicentre settings. Participants started and stopped closed-loop without supervision.. Weaknesses include a small sample size, an early generation closed-loop system (which is not a commercially available product), and a relatively short study duration.
In conclusion, day and night closed-loop can be used safely at home and its benefits include increased time when glucose is in target and reduced mean glucose.
Larger and longer studies are warranted. 
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